BRPI0810411B8 - derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica - Google Patents
derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêuticaInfo
- Publication number
- BRPI0810411B8 BRPI0810411B8 BRPI0810411A BRPI0810411A BRPI0810411B8 BR PI0810411 B8 BRPI0810411 B8 BR PI0810411B8 BR PI0810411 A BRPI0810411 A BR PI0810411A BR PI0810411 A BRPI0810411 A BR PI0810411A BR PI0810411 B8 BRPI0810411 B8 BR PI0810411B8
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- cell growth
- abnormal cell
- amide derivatives
- well
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
Abstract
derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu usos, bem como composição farmacêutica. a presente invenção se refere a um composto da fórmula i na qual r1 a r6, a, b, n e m são definidos aqui. tais novos derivados de sulfonil amida são úteis no tratamento de crescimento celular anormal, tal como câncer, em mamíferos. esta invenção também refere-se a uma método de usar tais compostos no tratamento de crescimento celular anormal em mamíferos, especialmente seres humanos, e às composições farmacêuticas contendo tais compostos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91259707P | 2007-04-18 | 2007-04-18 | |
PCT/IB2008/000845 WO2008129380A1 (en) | 2007-04-18 | 2008-04-07 | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0810411A2 BRPI0810411A2 (pt) | 2014-10-14 |
BRPI0810411B1 BRPI0810411B1 (pt) | 2019-09-10 |
BRPI0810411B8 true BRPI0810411B8 (pt) | 2021-05-25 |
Family
ID=39646361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0810411A BRPI0810411B8 (pt) | 2007-04-18 | 2008-04-07 | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
Country Status (33)
Country | Link |
---|---|
US (12) | US7928109B2 (pt) |
EP (1) | EP2146779B1 (pt) |
JP (1) | JP4782239B2 (pt) |
KR (1) | KR101132880B1 (pt) |
CN (2) | CN103951658B (pt) |
AP (1) | AP2009005010A0 (pt) |
AR (1) | AR066125A1 (pt) |
AU (1) | AU2008240359B2 (pt) |
BR (1) | BRPI0810411B8 (pt) |
CA (1) | CA2684447C (pt) |
CL (1) | CL2008001076A1 (pt) |
CO (1) | CO6260093A2 (pt) |
CU (1) | CU23813A3 (pt) |
DK (1) | DK2146779T3 (pt) |
DO (1) | DOP2009000248A (pt) |
EA (1) | EA016679B1 (pt) |
EC (1) | ECSP099694A (pt) |
ES (1) | ES2593486T3 (pt) |
GE (1) | GEP20125581B (pt) |
GT (1) | GT200900272A (pt) |
HK (2) | HK1200450A1 (pt) |
IL (3) | IL201468A (pt) |
MA (1) | MA31319B1 (pt) |
MX (1) | MX2009011090A (pt) |
NI (1) | NI200900190A (pt) |
NZ (1) | NZ580372A (pt) |
PA (1) | PA8777101A1 (pt) |
PE (1) | PE20090434A1 (pt) |
TN (1) | TN2009000428A1 (pt) |
TW (1) | TWI369205B (pt) |
UA (1) | UA97834C2 (pt) |
UY (1) | UY31026A1 (pt) |
WO (1) | WO2008129380A1 (pt) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009011090A (es) * | 2007-04-18 | 2009-11-02 | Pfizer Prod Inc | Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. |
UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
EP2268621A1 (en) * | 2008-03-20 | 2011-01-05 | Boehringer Ingelheim International GmbH | Regioselective preparation of substituted pyrimidines |
US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
WO2010025831A1 (de) * | 2008-09-03 | 2010-03-11 | Bayer Cropscience Ag | Heterozyklisch substituierte anilinopyrimidine als fungizide |
UY32240A (es) * | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
JP2010111702A (ja) | 2009-02-16 | 2010-05-20 | Tetsuya Nishio | 複素環化合物、その製造法および用途 |
CN101812016B (zh) * | 2009-02-23 | 2013-01-16 | 浙江海翔药业股份有限公司 | 一种制备依托昔布中间体-6-甲基烟酸及其酯的方法 |
EP2261211A1 (en) * | 2009-05-20 | 2010-12-15 | Université de Lille 2 Droit et Santé | 1,4-dihydropyridine derivatives and their uses |
TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
MX2011012961A (es) | 2009-06-05 | 2012-01-30 | Cephalon Inc | Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina. |
JP5539518B2 (ja) * | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製 |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
CA2797947C (en) * | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
EP2675794B1 (en) | 2011-02-17 | 2019-02-13 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
TWI681952B (zh) | 2011-04-22 | 2020-01-11 | 美商標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
RU2564419C1 (ru) * | 2011-07-28 | 2015-09-27 | Целльзом Лимитид | Гетероциклические аналоги пиримидина в качестве ингибиторов jak |
KR20140047092A (ko) | 2011-07-28 | 2014-04-21 | 셀좀 리미티드 | Jak 억제제로서의 헤테로시클릴 피리미딘 유사체 |
WO2013041652A1 (en) | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
EP2763985B1 (en) | 2011-10-07 | 2016-06-22 | Cellzome Limited | {(4-(4-morpholino-dihydrothieno[3,4-d]pyrimidin-2-yl)aryl}urea or carbamate derivatives as mtor inhibitors |
AU2012357038B2 (en) | 2011-12-23 | 2016-05-12 | Cellzome Limited | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
SG10201507865QA (en) * | 2012-03-06 | 2015-10-29 | Cephalon Inc | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
EP2855451B1 (en) | 2012-05-24 | 2017-10-04 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
AU2015204597B2 (en) * | 2014-01-09 | 2020-04-30 | Pfizer Inc. | Compositions and methods for treatment of abnormal cell growth |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US9962385B2 (en) | 2014-02-07 | 2018-05-08 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
CN106459048A (zh) | 2014-05-14 | 2017-02-22 | 辉瑞公司 | 吡唑并吡啶类和吡唑并嘧啶类 |
US9796685B2 (en) | 2014-12-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide |
ES2882954T3 (es) | 2014-12-16 | 2021-12-03 | Signal Pharm Llc | Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel |
WO2016100452A2 (en) * | 2014-12-17 | 2016-06-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US20180022710A1 (en) | 2015-01-29 | 2018-01-25 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
WO2017004192A1 (en) * | 2015-06-29 | 2017-01-05 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
CA2993173C (en) | 2015-07-24 | 2023-10-03 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
CN105111204B (zh) * | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 吡啶盐类酪氨酸激酶抑制剂、制备方法及其用途 |
CN105153150B (zh) * | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 一类吡啶盐类jak抑制剂、制备方法及其用途 |
CN105503860B (zh) * | 2015-10-13 | 2017-03-01 | 天津小新医药科技有限公司 | 一类腈基取代的吡啶盐类jak抑制剂、制备方法及其用途 |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
CN106279011A (zh) * | 2016-08-16 | 2017-01-04 | 成都百事兴科技实业有限公司 | 一种2,4‑二羟基‑6‑甲基烟酸乙酯的制备方法 |
WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
JP2021517589A (ja) | 2018-03-12 | 2021-07-26 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用 |
RU2761825C1 (ru) * | 2018-05-07 | 2021-12-13 | Хинова Фармасьютикалс Инк. | Соединения дейтерированного дефактиниба и их применение |
WO2020006724A1 (zh) * | 2018-07-05 | 2020-01-09 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
US20220040317A1 (en) * | 2018-09-27 | 2022-02-10 | Dana-Farber Cancer Institute, Inc. | Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use |
US20220125788A1 (en) * | 2018-12-27 | 2022-04-28 | Hinova Pharmaceuticals Inc. | FAK inhibitor and drug combination thereof |
WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
CN112592318B (zh) * | 2020-12-12 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用 |
CN112624966B (zh) * | 2020-12-25 | 2022-12-23 | 杭州澳赛诺生物科技有限公司 | 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法 |
KR20230117416A (ko) * | 2021-01-18 | 2023-08-08 | 하이노바 파마슈티컬스 인코포레이티드 | 아미노피리미딘계 fak 억제제 화합물의 합성 방법 |
CN113372334B (zh) * | 2021-05-25 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基-5-三氟甲基嘧啶衍生物及其应用 |
EP4349339A1 (en) * | 2021-05-25 | 2024-04-10 | Hinova Pharmaceuticals Inc. | Pharmaceutical composition for treatment of cancer and use thereof |
CN114716385B (zh) * | 2022-04-08 | 2024-03-12 | 北京师范大学 | 靶向粘着斑激酶的化合物及制备方法和应用 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
WO2024071371A1 (ja) * | 2022-09-30 | 2024-04-04 | ユビエンス株式会社 | 複素環式化合物 |
CN117105916B (zh) * | 2023-10-23 | 2024-01-16 | 希格生科(深圳)有限公司 | 苯并呋喃类化合物及其医药用途 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507146A (en) | 1982-12-28 | 1985-03-26 | Ciba-Geigy Corporation | 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
ATE263147T1 (de) | 1997-08-08 | 2004-04-15 | Pfizer Prod Inc | Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
IT1302431B1 (it) | 1998-08-12 | 2000-09-05 | Alasi Di Arcieri Franco & C S | Dispositivo di controllo di accessi in rete tramite il riconoscimentoveloce di trame applicative che soddisfano un insieme di regole |
DK1004578T3 (da) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
DK1282607T3 (en) | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
ES2542326T3 (es) | 2000-05-08 | 2015-08-04 | Janssen Pharmaceutica Nv | Inhibidores de la replicación del VIH |
US6630469B2 (en) | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
US6853233B1 (en) * | 2000-09-13 | 2005-02-08 | Infineon Technologies Ag | Level-shifting circuitry having “high” output impedance during disable mode |
IT1319686B1 (it) | 2000-12-12 | 2003-10-23 | C D Farmasint S R L | Procedimento di preparazione di citalopram. |
BR0116411A (pt) | 2000-12-21 | 2003-11-11 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
RS94703A (en) | 2001-05-29 | 2007-02-05 | Schering Aktiengesellschaft, | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2005500294A (ja) * | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
EP2090571B1 (de) | 2001-10-17 | 2012-05-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7008378B2 (en) * | 2002-03-07 | 2006-03-07 | Dean Melanie A | Patient conditional diagnosis assessment and symptom tracking system |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003231231A1 (en) * | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
EP1518855B1 (en) | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
AU2003285007A1 (en) | 2002-10-30 | 2004-06-07 | Merck & Co., Inc. | Kinase inhibitors |
EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
WO2004056807A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
SE0203820D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | chemical compounds |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1597237B1 (en) | 2003-02-07 | 2016-07-27 | Janssen Pharmaceutica NV | Pyrimidine derivatives for the prevention of HIV infection |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2005003103A2 (en) | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
AU2004259346A1 (en) | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
PL1660458T3 (pl) | 2003-08-15 | 2012-07-31 | Novartis Ag | 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
KR100694732B1 (ko) | 2003-09-05 | 2007-03-14 | 화이자 프로덕츠 인크. | Cf3-치환 피리미딘의 선택적 합성 |
US7363505B2 (en) * | 2003-12-03 | 2008-04-22 | Pen-One Inc | Security authentication method and system |
WO2005111016A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0510980A (pt) * | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento do crescimento anormal de células |
WO2005111023A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0511132A (pt) | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina e composição farmacêutica compreendendo os mesmos |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
DE602005011279D1 (de) | 2004-06-04 | 2009-01-08 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
JP4990766B2 (ja) | 2004-07-01 | 2012-08-01 | シンタ ファーマシューティカルズ コーポレーション | 二置換型ヘテロアリール化合物 |
US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
AU2005295788A1 (en) | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
AU2006272837B2 (en) | 2005-07-21 | 2012-08-23 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of MEK |
CA2632149C (en) | 2005-12-01 | 2011-11-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
AU2006327871A1 (en) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
MX2009011090A (es) * | 2007-04-18 | 2009-11-02 | Pfizer Prod Inc | Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. |
-
2008
- 2008-04-07 MX MX2009011090A patent/MX2009011090A/es active IP Right Grant
- 2008-04-07 EA EA200901250A patent/EA016679B1/ru not_active IP Right Cessation
- 2008-04-07 AU AU2008240359A patent/AU2008240359B2/en active Active
- 2008-04-07 CN CN201410067096.3A patent/CN103951658B/zh active Active
- 2008-04-07 NZ NZ580372A patent/NZ580372A/en unknown
- 2008-04-07 EP EP08719431.2A patent/EP2146779B1/en active Active
- 2008-04-07 CA CA2684447A patent/CA2684447C/en active Active
- 2008-04-07 KR KR1020097023931A patent/KR101132880B1/ko active IP Right Grant
- 2008-04-07 CN CN200880019325.7A patent/CN101678215B/zh active Active
- 2008-04-07 JP JP2010503606A patent/JP4782239B2/ja active Active
- 2008-04-07 ES ES08719431.2T patent/ES2593486T3/es active Active
- 2008-04-07 BR BRPI0810411A patent/BRPI0810411B8/pt active IP Right Grant
- 2008-04-07 DK DK08719431.2T patent/DK2146779T3/en active
- 2008-04-07 GE GEAP200811513A patent/GEP20125581B/en unknown
- 2008-04-07 UA UAA200910461A patent/UA97834C2/ru unknown
- 2008-04-07 WO PCT/IB2008/000845 patent/WO2008129380A1/en active Application Filing
- 2008-04-07 AP AP2009005010A patent/AP2009005010A0/xx unknown
- 2008-04-15 CL CL200801076A patent/CL2008001076A1/es unknown
- 2008-04-16 PA PA20088777101A patent/PA8777101A1/es unknown
- 2008-04-16 UY UY31026A patent/UY31026A1/es not_active Application Discontinuation
- 2008-04-17 PE PE2008000674A patent/PE20090434A1/es not_active Application Discontinuation
- 2008-04-17 US US12/105,151 patent/US7928109B2/en active Active
- 2008-04-17 TW TW097113908A patent/TWI369205B/zh active
- 2008-04-18 AR ARP080101626A patent/AR066125A1/es not_active Application Discontinuation
-
2009
- 2009-10-12 IL IL201468A patent/IL201468A/en not_active IP Right Cessation
- 2009-10-16 CU CU20090175A patent/CU23813A3/es not_active IP Right Cessation
- 2009-10-16 MA MA32288A patent/MA31319B1/fr unknown
- 2009-10-16 GT GT200900272A patent/GT200900272A/es unknown
- 2009-10-16 EC EC2009009694A patent/ECSP099694A/es unknown
- 2009-10-16 NI NI200900190A patent/NI200900190A/es unknown
- 2009-10-16 DO DO2009000248A patent/DOP2009000248A/es unknown
- 2009-10-16 TN TNP2009000428A patent/TN2009000428A1/fr unknown
- 2009-10-16 CO CO09115844A patent/CO6260093A2/es not_active Application Discontinuation
-
2010
- 2010-05-19 HK HK15100919.1A patent/HK1200450A1/xx unknown
- 2010-05-19 HK HK10104930.3A patent/HK1136985A1/xx unknown
-
2011
- 2011-03-11 US US13/045,923 patent/US8247411B2/en active Active
-
2012
- 2012-07-24 US US13/557,049 patent/US8440822B2/en active Active
-
2013
- 2013-03-29 US US13/853,483 patent/US20140100368A1/en not_active Abandoned
-
2014
- 2014-05-08 IL IL232511A patent/IL232511B/en active IP Right Grant
- 2014-11-24 US US14/552,153 patent/US20150080368A1/en not_active Abandoned
-
2016
- 2016-01-19 US US15/000,944 patent/US20160130250A1/en not_active Abandoned
- 2016-09-12 US US15/263,041 patent/US20170001981A1/en not_active Abandoned
-
2017
- 2017-04-20 US US15/492,719 patent/US20170327485A1/en not_active Abandoned
-
2018
- 2018-04-05 US US15/946,117 patent/US10450297B2/en active Active
- 2018-07-12 IL IL260560A patent/IL260560B/en active IP Right Grant
-
2019
- 2019-09-11 US US16/567,675 patent/US20200002310A1/en not_active Abandoned
-
2021
- 2021-08-27 US US17/458,862 patent/US20220251066A1/en not_active Abandoned
-
2023
- 2023-03-15 US US18/121,809 patent/US20240109862A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0810411B8 (pt) | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica | |
HN2005000212A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
CU23847B1 (es) | 2-piperidinilo bencimidazoles útiles en el tratamiento del crecimiento celular anormal | |
UY28894A1 (es) | Derivados de pirimidina para tratar el crecimiento celular anómalo | |
BRPI0923702B8 (pt) | Composições inseticidas estáveis compreendendo spinosin e uma mistura esteroisomérica de sulfoxaflor, e seu método de produção | |
BRPI0911035B8 (pt) | ativadores de pirrolidinona glicoquinase | |
GT200300296A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
CR8266A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
BR112012030923B8 (pt) | Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo | |
BRPI0510963A (pt) | derivados pirimidina para o tratamento do crescimento anormal de células | |
CR10288A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
DOP2006000061A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
BRPI0819655A2 (pt) | compostos indol, composição farmacêutica, e, processo para preparar uma composição farmacêutica | |
UY32077A (es) | Inhibidores de quinasa tipo polo | |
UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
BR112012026147A2 (pt) | espiroderivados azacíclicos como inibidores de hsl | |
BR112012014721A2 (pt) | composição de hormônio do crescimento | |
PA8855001A1 (es) | Monocarbamas | |
UY31138A1 (es) | Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones | |
DOP2009000214A (es) | Macrolidos basados en eritromicina | |
UY31953A (es) | 3-cianopirrolidinil-fenil-oxazolidinonas como agentes antibacterianos | |
CU20060216A7 (es) | Derivados de pirimidina para tratar el crecimiento celular anómalo | |
DOP2005000086A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
UY28136A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
SV2006002113A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo ref. pc32279a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |